As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|A Study of Pembrolizumab in Pediatric Participants With an Advanced Solid Tumor or Lymphoma||051||
||Phase 1/Phase 2||Recruiting|
|Safety and Efficacy of Pembrolizumab in Children and Young Adults With Classical Hodgkin Lymphoma||667||Hodgkin Lymphoma||Phase 2||Recruiting|